查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870104

支气管痉挛治疗市场按治疗方法、药物类别、给药途径、通路和最终用户划分－2025年至2032年全球预测

Bronchial Spasms Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，支气管痉挛治疗市场将成长至 4.4077 亿美元，复合年增长率为 4.50%。

关键市场统计数据
基准年 2024 3.0972亿美元
预计年份：2025年 3.2386亿美元
预测年份 2032 4.4077亿美元
复合年增长率 (%) 4.50%

本书权威概述了支气管痉挛的临床挑战、治疗方法的多样性、患者需求以及当代治疗路径中相关人员的决策因素。

支气管痉挛是一种阵发性但常反覆发作的下呼吸道狭窄事件，对患者和临床诊疗带来沉重负担。其病理生理机制涉及气道高反应性，包括平滑肌收缩、黏膜水肿和多种发炎过程，因此需要快速缓解症状并制定预防復发的策略。临床医师需要在急性期治疗和长期控制气道发炎之间取得平衡，这种平衡决定了不同临床环境下的治疗选择。因此，治疗方案涵盖了以器械为基础的给药系统、注射生物製药和全身性用药，以及针对不同作用机制的口服药物。

精准医疗、先进的吸入平台和不断发展的护理模式将如何重塑支气管痉挛治疗的临床选择和商业性路径

近年来，治疗方法和护理模式的同步发展，彻底改变了支气管痉挛的治疗方式。在治疗方面，精准生物製药和优化的吸入技术拓展了临床治疗手段，使针对不同表型患者群体的个人化介入成为可能。与药理学进步相辅相成的是，粉剂和气雾剂给药装置的创新，尤其註重剂量精准、使用便利性和依从性支持，这些创新正在共同改变临床医生选择和处方治疗方案的方式。数位化依从性工具和远端监测的日益普及进一步强化了这些变革，使患者能够进行长期管理，而不仅限于间歇性就诊。

评估2025年美国关税变化对支气管痉挛治疗的供应链、製造业经济、筹资策略和临床连续性的实际影响

2025年美国关税调整的累积影响已对支气管痉挛治疗生态系统中的相关人员产生了实际影响。由于关税上涨，原料药、计量阀和特殊聚合物等医疗设备组件以及进口生产设备的成本增加，给生产经济效益带来了上行压力。为此，赞助商和契约製造正采取措施降低贸易政策波动带来的风险，例如重新评估供应商协议、加速双重采购策略，以及在某些情况下将关键组装业务迁至更靠近主要市场的地方。

详细的細項分析将治疗方法、剂型、药物类别、通路和临床环境与临床应用和商业化的驱动因素联繫起来

透过对治疗方法、药物类别、给药途径、分销管道和最终用户进行详细的細項分析，重点关注治疗创新与商业性机会的交汇点。不同类型的治疗方法呈现出复杂的格局，吸入、注射和口服药物各自发挥不同的作用。在吸入疗法中，干粉吸入器、定量喷雾吸入器和雾化器各自提供不同的给药方案。干粉吸入器分为多次使用和一次性使用两种类型，而雾化器则分为喷射式、网式和超音波技术。注射药物包括氨茶碱、生物製药和全身性糖皮质激素，其中生物製药又细分为美泊利单抗、Omalizumab和瑞利珠单抗等药物。口服药物包括抗胆碱能药物、支气管扩张剂、联合治疗和皮质类固醇。抗胆碱能药物分为长效和短效，支气管扩张剂分为长效β受体激动剂和短效β受体激动剂，皮质类固醇有吸入剂和全身用药两种剂型。

美洲、欧洲、中东和非洲以及亚太地区在监管、支付方和基础设施方面的差异将如何影响普及趋势和存取策略

区域趋势对全球支气管痉挛药物的采纳、报销和临床应用有显着影响。在美洲，支付方的积极参与、注重降低住院率的疗效导向以及先进吸入装置的广泛应用，往往是推动临床应用的主要因素。该地区的市场进入策略通常优先考虑可靠的真实世界证据，并加强对呼吸系统科医生和基层医疗网络的相关人员教育。在欧洲、中东和非洲，监管的多样性和报销体系的不均衡造成了多种多样的准入途径，而区域性的卫生技术评估要求和采购惯例要求制定定制化的证据文件和弹性价格设定策略。同时，在亚太地区，数位医疗的快速普及、对本土生产能力的日益重视以及支付方成熟度的差异，正在影响着给药途径和分销渠道的选择，其中在线药房和居家医疗服务在某些市场正迅速发展。

对医药、医疗设备和数位市场新参与企业的竞争分析表明，协作、证据生成和生产敏捷性是其差异化优势。

支气管痉挛治疗领域的竞争格局错综复杂，既有老牌製药和医疗设备公司，也有新兴的专业研发公司，以及数量不断成长的数位医疗参与企业。拥有广泛呼吸系统产品组合的现有公司往往凭藉其在製剂研发、医疗设备设计和全球分销网络方面的综合能力来维持市场地位。同时，规模较小的专业公司则专注于新型作用机制和差异化给药技术，从而占据了利基市场。医疗设备开发商和生物製药开发商之间的合作日益密切，致力于开发旨在提高患者用药依从性和改善临床疗效的联合解决方案。

针对製造商和供应商的具体策略行动，旨在加强供应韧性、促进合规性、产生令人信服的真实世界证据并加快获取途径。

产业领导者应优先考虑兼顾临床价值和商业性韧性的实际措施。首先，应实现关键零件和原料筹资策略的多元化，以降低关税和地缘政治干扰带来的风险，同时评估近岸外包和双重采购机会，以缩短前置作业时间。其次，应投资于医疗设备的易用性和依从性工具，将客观的依从性测量和病患教育融入产品中，以改善治疗效果并提高支付方的接受度。第三，应制定严谨的真实世界证据产生计划，以获取符合支付方要求的具有临床意义的终点指标和卫生经济学结果，从而促进获得有利的准入决策。

一种透明且多方面的调查方法，结合了临床医生的见解、文献综述和交叉检验分析，从而得出严谨的产业洞察。

本分析的调查方法结合了定性和定量技术，以确保对临床实践、医疗设备应用、支付方行为和供应动态进行多方面且平衡的分析。主要研究包括对呼吸系统科医生、呼吸科护理师、采购人员和报销专家进行结构化访谈，以收集他们对治疗选择、设备易用性和获取障碍的本地观点。次要证据来自同行评审的临床文献、监管指导文件、医疗设备性能规范和已发布的临床指南，以阐明主要研究结果并检验基于机制的合理性。

简明扼要地总结了治疗方法、营运和政策趋势，重点是将创新转化为临床影响和商业性成功的策略重点。

摘要，支气管痉挛的治疗正在经历重大变革，这主要得益于标靶治疗、给药技术和医疗服务模式的进步。这些变革为改善患者预后创造了机会，例如更精准的治疗方法与表型匹配、透过先进的吸入和雾化系统实现可靠的给药，以及加强依从性监测。同时，贸易政策变化和区域监管差异等宏观因素迫使企业在生产、采购和打入市场策略更加深思熟虑。那些能够将临床创新与营运韧性以及符合支付方期望的循证实践相结合的机构将取得最大的成功。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 针对支气管痉挛发炎路径的生物製药疗法（例如单株抗体）发展迅速
  • 增加长效毒蕈碱受体拮抗剂的使用，以改善慢性阻塞性气道疾病的支气管平滑肌鬆弛。
  • 采用具有依从性监测和即时回馈功能的数位吸入器来优化支气管痉挛控制
  • 扩大吸入双效支气管扩张剂和皮质类固醇联合疗法的应用范围，以减少支气管痉挛性疾病的急性发作。
  • 急诊室越来越多地使用雾化硫酸镁治疗急性支气管痉挛（仿单标示外）。
  • 开发一种新型的基于奈米颗粒的气溶胶递送系统，用于支气管痉挛的靶向支气管扩张剂治疗
  • 老年患者对具有更高安全性和耐受性的个人化支气管痉挛治疗的需求日益增长
  • 监管部门核准加速新一代生物製药在严重、难治性气喘相关支气管痉挛的应用
  • 远端医疗平台对服务不足地区慢性支气管痉挛患者远距监测和管理的影响
  • 利用基于生物标记的精准医疗方法，客製化支气管痉挛治疗方法

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗类型分類的支气管痉挛治疗市场

  • 吸入疗法
    • 干粉吸入器
      • 多剂量干粉吸入器
      • 单剂量干粉吸入器
    • 定量喷雾吸入器
    • 喷雾器
      • 喷射式雾化器
      • 筛孔式喷雾器
      • 超音波雾化器
  • 注射药物
    • 氨茶碱
    • 生物製药
      • 美泊利单抗
      • Omalizumab
      • 瑞利珠单抗
    • 全身性皮质类固醇
  • 口服药物
    • 抗胆碱能药物
      • 长效抗胆碱能药物
      • 短效抗胆碱能药物
    • 支气管扩张剂
      • 长效β2受体激动剂
      • 短效β2受体激动剂
    • 联合治疗
    • 皮质类固醇
      • 吸入性皮质类固醇
      • 全身性皮质类固醇

9. 按药物类别分類的支气管痉挛治疗市场

  • 抗胆碱能药物
    • 长效抗胆碱能药物
    • 短效抗胆碱能药物
  • β-激动剂
    • 长效β2受体激动剂
    • 短效β2受体激动剂
  • 皮质类固醇
    • 吸入性皮质类固醇
    • 全身性皮质类固醇
  • 白三烯调节剂
    • Montelukast
    • 札菲尔库斯特
    • 吉留顿

第十章 按给药途径分類的支气管痉挛治疗市场

  • 吸入
    • 气雾剂
    • 干粉
    • 雾化
  • 注射
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 口服
    • 胶囊
    • 糖浆
    • 药片
  • 经皮
    • 凝胶
    • 修补

第十一章 支气管痉挛治疗市场（依通路划分）

  • 诊所
    • 门诊部
    • 专科诊所
  • 医院药房
    • 私立医院
    • 公立医院
  • 网路药房
    • 杂交种
    • 纯线上销售
  • 零售药房
    • 连锁药局
    • 独立药房

第十二章 支气管痉挛治疗市场（依最终使用者划分）

  • 门诊手术中心
  • 诊所
    • 门诊部
    • 专科诊所
  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院

第十三章 各地区支气管痉挛治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 支气管痉挛治疗市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国支气管痉挛治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Merck & Co., Inc.
    • Viatris Inc.
    • Cipla Limited
    • Sumitomo Pharma Co., Ltd.
Product Code: MRR-3204321AF1B0

The Bronchial Spasms Treatment Market is projected to grow by USD 440.77 million at a CAGR of 4.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 309.72 million
Estimated Year [2025] USD 323.86 million
Forecast Year [2032] USD 440.77 million
CAGR (%) 4.50%

An authoritative overview of bronchial spasm clinical imperatives, therapeutic diversity, patient needs, and stakeholder decision drivers in modern care pathways

Bronchial spasms are episodic but frequently recurrent constrictive events of the lower airways that impose significant clinical burden on patients and clinical pathways. The pathophysiology involves hyperreactive airways with smooth muscle constriction, mucosal edema, and variable inflammatory processes that require rapid symptom relief as well as strategies to prevent recurrence. Clinicians balance acute management with long-term modulation of airway inflammation, and this balance shapes therapeutic choices across numerous care settings. As a result, the treatment landscape includes device-based delivery systems, injectable biologics and systemic agents, and oral therapies that address different mechanistic targets.

Against this clinical backdrop, stakeholders must navigate device usability, adherence dynamics, regulatory expectations, and evolving reimbursement environments that influence product adoption. Patients increasingly demand treatments that minimize exacerbation risk while preserving quality of life, and payers prioritize therapies that reduce hospital encounters and downstream costs. Consequently, industry participants are under pressure to demonstrate real-world effectiveness, patient-centered design, and cost-effectiveness in order to secure favorable uptake across ambulatory clinics, hospital systems, and home-care settings. This introduction frames the subsequent sections by highlighting the intersection of clinical need, therapeutic diversity, and commercial imperatives.

How precision therapeutics, advanced inhalation platforms, and care model evolution are reshaping clinical choices and commercial pathways for bronchial spasm management

Recent years have seen transformative shifts in bronchial spasms treatment driven by simultaneous advances in therapeutic modalities and care delivery models. On the therapeutic front, precise biologic agents and optimized inhalation technologies have broadened the clinical toolkit, allowing more tailored interventions for phenotypically distinct patient cohorts. Complementing pharmacologic progress, device innovation in powder and aerosol delivery has emphasized dosing accuracy, ease of use, and adherence support, which together are shifting how clinicians select and prescribe therapies. These changes are amplified by greater integration of digital adherence tools and remote monitoring, enabling longitudinal patient management beyond episodic clinic encounters.

Regulatory and reimbursement environments have evolved in parallel, with payers increasingly requesting robust real-world evidence and value-based outcomes that demonstrate reductions in acute care utilization. Meanwhile, supply chain resilience and manufacturing agility have gained prominence due to prior disruptions, prompting sponsors to diversify sourcing and localize critical components. In sum, the landscape is moving toward personalized, evidence-driven care pathways that couple targeted therapies with advanced delivery systems and data-rich performance measurement, reshaping clinical practice and commercial strategies alike.

Assessment of the practical effects of 2025 United States tariff changes on supply chains, manufacturing economics, procurement strategies, and clinical continuity for bronchial spasm treatments

The cumulative effects of the United States tariff adjustments implemented in 2025 have introduced practical implications for participants across the bronchial spasms treatment ecosystem. Tariff-driven increases in the cost of active pharmaceutical ingredients, device components such as metering valves and specialized polymers, and imported manufacturing equipment have exerted upward pressure on production economics. Sponsors and contract manufacturers have responded by re-examining supplier contracts, accelerating dual-sourcing strategies, and in some cases relocating critical assembly steps closer to key markets to mitigate exposure to trade policy volatility.

Beyond direct cost impacts, tariffs have influenced strategic prioritization of capital expenditure, with manufacturers weighing the returns of investing in localized production against the benefits of maintaining globalized supply chains. Payers and providers have also felt secondary effects; procurement negotiations now factor in longer lead times and potential price variability, which can affect formulary positioning and purchasing cadence. Looking forward, the industry is adapting through a combination of contractual hedging, increased inventory buffers for critical components, and collaborative engagements with logistics partners to preserve continuity of care without compromising regulatory compliance or clinical quality standards.

In-depth segmentation analysis linking therapeutic modalities, delivery formats, drug classes, channels, and care settings to clinical adoption and commercialization levers

A granular segmentation lens clarifies where therapeutic innovation and commercial opportunity intersect across treatment types, drug classes, administration routes, distribution channels, and end users. Examining treatment type reveals a multi-modal landscape in which inhalation therapy, injectable medications, and oral medications play distinct roles. Within inhalation therapy, dry powder inhalers, metered dose inhalers, and nebulizers represent differentiated delivery profiles; dry powder devices subdivide into multi-dose and single-dose formats, while nebulizers split into jet, mesh, and ultrasonic technologies. Injectable options include aminophylline, biologics, and systemic steroids, with biologics further differentiated by agents such as mepolizumab, omalizumab, and reslizumab. Oral medications encompass anticholinergics, bronchodilators, combination therapies, and corticosteroids, with anticholinergics separating into long-acting and short-acting variants and bronchodilators into long-acting and short-acting beta agonists, while corticosteroids appear as inhaled and systemic formulations.

When viewed by drug class, distinctions among anticholinergics, beta agonists, corticosteroids, and leukotriene modifiers influence prescribing patterns and payer assessments, and subclasses within each category affect clinical positioning. Route of administration further refines opportunity sets: inhalation modalities span aerosol, dry powder, and nebulization approaches; injectables cover intramuscular, intravenous, and subcutaneous routes; oral therapies are delivered in capsule, syrup, or tablet formats; and transdermal options include gels and patches. Distribution channel dynamics shape access and patient experience, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each subdivided by practice type or retail model. Finally, end-user segmentation highlights distinct care settings-ambulatory surgical centers, clinics, home care, and hospitals-with outpatient and specialist clinics as key subsegments and private and public hospital distinctions that affect procurement and clinical protocols. Together, these segmentation layers inform product design, commercialization tactics, and evidence generation priorities by aligning therapeutic attributes to the operational realities of each channel and user type.

How regional regulatory, payer, and infrastructure differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption dynamics and access strategies

Regional dynamics materially influence how bronchial spasms therapies are adopted, reimbursed, and integrated into clinical practice across the globe. In the Americas, clinical adoption tends to be driven by strong payer engagement, emphasis on outcomes that reduce hospital utilization, and widespread availability of advanced inhalation devices; market access strategies there typically prioritize robust real-world evidence and stakeholder education for pulmonologists and primary care networks. In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement systems create a mosaic of access pathways, where localized health technology assessment requirements and procurement practices necessitate tailored evidence dossiers and flexible pricing approaches. Meanwhile, in the Asia-Pacific region, rapid uptake of digital health, a growing emphasis on domestic manufacturing capability, and varied payer maturity influence both route-of-administration preferences and distribution channel choices, with online pharmacies and home-care services expanding rapidly in certain markets.

Across all regions, differences in clinician training, patient preferences, and healthcare infrastructure shape which delivery systems and therapeutic classes gain traction. These regional contrasts underscore the need for differentiated commercialization plans, adaptive clinical support programs, and supply chain footprints that align with regulatory timelines and local procurement norms. Consequently, strategic planning must incorporate region-specific evidence generation, stakeholder engagement, and logistical arrangements to ensure treatment innovations translate into measurable improvements in patient outcomes and care continuity.

Analysis of competitive behaviors among pharmaceutical, device, and digital entrants emphasizing collaboration, evidence generation, and manufacturing agility as differentiators

Competitive dynamics in the bronchial spasms treatment space reflect a blend of established pharmaceutical and device players, emerging specialty developers, and a growing cohort of digital health entrants. Incumbent firms with broad respiratory portfolios tend to leverage integrated capabilities-spanning formulation, device engineering, and global distribution-to sustain market presence, while smaller specialist companies focus on novel mechanisms or differentiated delivery technologies to carve niche positions. Collaboration between device and biologic developers has become more frequent, producing combination solutions that aim to improve adherence and clinical outcomes.

Strategic priorities among companies include strengthening clinical pipelines with targeted indications, investing in user-centric device design to reduce misuse, and generating robust real-world evidence to satisfy payer demands. Manufacturing agility and regulatory savvy are also competitive differentiators, as firms that can localize production, expedite regulatory submissions, and provide post-market safety data tend to achieve smoother market entry. Mergers, strategic partnerships, and licensing arrangements remain important mechanisms for accelerating access to complementary capabilities, while commercialization success often hinges on the depth of clinical stakeholder relationships and the ability to demonstrate measurable reductions in acute care episodes.

Concrete strategic actions for manufacturers and providers to strengthen supply resilience, drive adherence, generate compelling real-world evidence, and accelerate access

Industry leaders should prioritize a set of pragmatic actions that align clinical value with commercial resilience. First, diversify sourcing strategies for critical components and raw materials to reduce exposure to tariff-related and geostrategic disruptions, while evaluating opportunities for nearshoring or dual-sourcing to shorten lead times. Second, invest in device usability and adherence support tools, integrating objective adherence measures and patient education into product offerings to improve therapeutic outcomes and payer receptivity. Third, develop rigorous real-world evidence generation plans that capture clinically meaningful endpoints and health economic outcomes aligned with payer requirements to facilitate favorable access decisions.

Additionally, forge collaborative partnerships with healthcare systems and specialty clinics to streamline patient pathways and collect longitudinal outcome data that demonstrate value. Enhance regulatory engagement early to align clinical development with regional submission expectations, and consider staged rollouts that prioritize high-value care settings. Finally, adopt flexible pricing and contracting approaches, including outcome-based arrangements where appropriate, to lower payer barriers and accelerate adoption. Implementing these strategies will help organizations translate scientific advances into durable clinical impact and sustainable commercial performance.

Transparent description of multi-source research techniques combining clinician insights, literature synthesis, and cross-validated analysis to produce rigorous industry findings

The research approach underpinning this analysis combined qualitative and quantitative techniques to ensure balanced, multi-source insight into clinical practice, device adoption, payer behavior, and supply dynamics. Primary research included structured interviews with pulmonologists, respiratory nurses, procurement leaders, and reimbursement specialists to capture frontline perspectives on treatment selection, device usability, and access barriers. Secondary evidence was synthesized from peer-reviewed clinical literature, regulatory guidance documents, device performance specifications, and published clinical guidelines to contextualize primary findings and to validate mechanistic rationale.

Analytical rigor was achieved through cross-validation of themes across data sources, targeted case studies of representative product launches, and scenario-based analysis of supply chain and policy shocks. Limitations of the methodology are acknowledged: stakeholder interviews may reflect practice variation, and publicly available literature may lag the most recent commercial developments. To mitigate these constraints, the study applied conservative interpretation of emerging trends and prioritized triangulated findings that appeared consistently across independent sources. Where relevant, the research identifies evidence gaps and recommends follow-up primary studies to address critical uncertainties.

Concise synthesis of therapeutic, operational, and policy dynamics highlighting strategic priorities for converting innovation into clinical impact and commercial success

In summary, bronchial spasms treatment is undergoing a phase of substantive evolution driven by advances in targeted therapeutics, delivery technologies, and care delivery models. These shifts create opportunities to improve patient outcomes through better matching of therapeutic modality to phenotype, more reliable delivery through refined inhalation and nebulization systems, and enhanced adherence monitoring. At the same time, macro forces such as trade policy changes and regional regulatory heterogeneity require companies to be more deliberate in their manufacturing, sourcing, and market-entry strategies. Successful organizations will be those that combine clinical innovation with operational resilience and evidence generation tailored to payer expectations.

Decision-makers should view the current environment as one where coordinated investments across product design, clinical evidence programs, and supply chain architecture can yield competitive advantage. By aligning technical development with stakeholder needs and regional access dynamics, leaders can convert scientific promise into reproducible clinical benefit and sustainable commercial performance. The following call to action outlines options for acquiring the full report and arranging targeted briefings to translate these insights into immediate strategic plans.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth in biologic therapies targeting inflammatory pathways in bronchial spasms such as monoclonal antibodies
  • 5.2. Rising adoption of long-acting muscarinic antagonists for improved bronchial muscle relaxation in chronic obstructive airway diseases
  • 5.3. Emergence of digital inhaler devices with adherence monitoring and real time feedback to optimize bronchial spasm control
  • 5.4. Expansion of combination inhaler therapies with dual bronchodilators and corticosteroids to reduce exacerbations in bronchospastic conditions
  • 5.5. Increasing off label use of nebulized magnesium sulfate in emergency departments for acute bronchospasm management
  • 5.6. Development of novel nanoparticle based aerosol delivery systems for targeted bronchodilator therapy in bronchial spasms
  • 5.7. Rising demand among elderly patients for personalized bronchial spasm treatments with improved safety and tolerability profiles
  • 5.8. Regulatory approvals accelerating the launch of next generation biologics for severe uncontrolled asthma related bronchial spasms
  • 5.9. Impact of telemedicine platforms on remote monitoring and management of chronic bronchial spasm patients in underserved regions
  • 5.10. Advancements in biomarker driven and precision medicine approaches to customize bronchial spasm treatment regimens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchial Spasms Treatment Market, by Treatment Type

  • 8.1. Inhalation Therapy
    • 8.1.1. Dry Powder Inhalers
      • 8.1.1.1. Multi-Dose Dpi
      • 8.1.1.2. Single-Dose Dpi
    • 8.1.2. Metered Dose Inhalers
    • 8.1.3. Nebulizers
      • 8.1.3.1. Jet Nebulizers
      • 8.1.3.2. Mesh Nebulizers
      • 8.1.3.3. Ultrasonic Nebulizers
  • 8.2. Injectable Medications
    • 8.2.1. Aminophylline
    • 8.2.2. Biologics
      • 8.2.2.1. Mepolizumab
      • 8.2.2.2. Omalizumab
      • 8.2.2.3. Reslizumab
    • 8.2.3. Systemic Steroids
  • 8.3. Oral Medications
    • 8.3.1. Anticholinergics
      • 8.3.1.1. Long-Acting Anticholinergics
      • 8.3.1.2. Short-Acting Anticholinergics
    • 8.3.2. Bronchodilators
      • 8.3.2.1. Long-Acting Beta Agonists
      • 8.3.2.2. Short-Acting Beta Agonists
    • 8.3.3. Combination Therapies
    • 8.3.4. Corticosteroids
      • 8.3.4.1. Inhaled Steroids
      • 8.3.4.2. Systemic Steroids

9. Bronchial Spasms Treatment Market, by Drug Class

  • 9.1. Anticholinergics
    • 9.1.1. Long-Acting Anticholinergics
    • 9.1.2. Short-Acting Anticholinergics
  • 9.2. Beta Agonists
    • 9.2.1. Long-Acting Beta Agonists
    • 9.2.2. Short-Acting Beta Agonists
  • 9.3. Corticosteroids
    • 9.3.1. Inhaled Corticosteroids
    • 9.3.2. Systemic Corticosteroids
  • 9.4. Leukotriene Modifiers
    • 9.4.1. Montelukast
    • 9.4.2. Zafirlukast
    • 9.4.3. Zileuton

10. Bronchial Spasms Treatment Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Aerosol
    • 10.1.2. Dry Powder
    • 10.1.3. Nebulization
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Syrup
    • 10.3.3. Tablet
  • 10.4. Transdermal
    • 10.4.1. Gel
    • 10.4.2. Patch

11. Bronchial Spasms Treatment Market, by Distribution Channel

  • 11.1. Clinics
    • 11.1.1. Outpatient Clinics
    • 11.1.2. Specialist Clinics
  • 11.2. Hospital Pharmacies
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Online Pharmacies
    • 11.3.1. Hybrid
    • 11.3.2. Pure Play
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain Pharmacies
    • 11.4.2. Independent Pharmacies

12. Bronchial Spasms Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
    • 12.2.1. Outpatient Clinics
    • 12.2.2. Specialist Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
    • 12.4.1. Private Hospitals
    • 12.4.2. Public Hospitals

13. Bronchial Spasms Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchial Spasms Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchial Spasms Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. AstraZeneca plc
    • 16.3.3. Boehringer Ingelheim International GmbH
    • 16.3.4. Novartis AG
    • 16.3.5. Teva Pharmaceutical Industries Ltd.
    • 16.3.6. Sanofi S.A.
    • 16.3.7. Merck & Co., Inc.
    • 16.3.8. Viatris Inc.
    • 16.3.9. Cipla Limited
    • 16.3.10. Sumitomo Pharma Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRONCHIAL SPASMS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL BRONCHI